Ensysce Biosciences (ENSC) stock

Market cap $7.7MShares as of Aug 12

$0.40
-1.20%

Market closed. Prices as of Friday's close.

Not scored

Breakaway doesn't score ENSC. It is too small and priced too low for a fair Quality Score.

Healthcare · Biotech

Follow ENSC's trial news. Pro members can get an alert when Ensysce Biosciences files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when ENSC files news on its trialsSee it live, free for 24 hours. No account needed. Then keep going with a free account.

We do the work for you. 3,243 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live. So can you, free, with no account.

What's next for ENSC, and how long its cash lasts

From Ensysce Biosciences’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Its trials

A trial underway
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With NafamostatPhase 1 · Recruiting · 54 people · main data estimated Dec 22, 2026 · NCT06500793

1 more trial, 45 filings, for Pro members.

Cash runway

The company says its cash lasts into late 2027 (8-K, Aug 13).

That is the company's own estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration of its own or at-the-market program on file in the last three years.

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: 4 raises and their amounts, and the share count against a year ago.

Insiders

Director Bob G Gower bought 908,614 shares on Aug 7.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

For Pro members: every trade.

Get an optional alert when ENSC files news on its trialsSee it live, free for 24 hours. No account needed. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 114 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

ENSC's latest filings

24 more filings in the last year, for Pro members

From SEC EDGAR, as filed. Each opens the filing on the SEC's site.

Why ENSC isn't scored

The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares a day. ENSC is worth about $7.7M and trades at $0.40. A stock that clears every mark is scored from the next weekly rebuild.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price on this page is delayed at least 15 minutes. The share count and the filings are shown as filed.